DEXTROMETHORPHAN AND MEPHENYTOIN PHENOTYPING OF PATIENTS TREATED WITH THIORIDAZINE OR AMITRIPTYLINE

被引:73
作者
BAUMANN, P
MEYER, JW
AMEY, M
BAETTIG, D
BRYOIS, C
JONZIERPEREY, M
KOEB, L
MONNEY, C
WOGGON, B
机构
[1] UNIV LAUSANNE,HOP CERY,DEPT PSYCHIAT ADULTE,PSYCHOPHARMACOL CLIN,CH-1008 PRILLY,SWITZERLAND
[2] UNIV ZURICH,PSYCHIAT CLIN,CH-8006 ZURICH,SWITZERLAND
关键词
PHARMACOGENETICS OF METABOLISM; AMITRIPTYLINE; THIORIDAZINE; DEXTROMETHORPHAN TEST; MEPHENYTOIN TEST; PSYCHIATRIC PATIENTS;
D O I
10.1097/00007691-199202000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The metabolism of most tricyclic antidepressants and some phenothiazine neuroleptics is under the genetic control of hepatic cytochrome P-450IID6, which also regulates the metabolism of dextromethorphan. This study investigated the effect of treatment with amitriptyline or thioridazine on testing for genetically regulated efficiency of the metabolism of dextromethorphan and mephenytoin. One group of 33 patients was treated with 150 mg amitriptyline a day (the AMI group); 25 other patients received a daily dose of thioridazine, either 200 mg (200-THD group; n = 7) or 400 mg (400-THD group; n = 18). Before and after 10 days of this treatment, all patients were tested with 25 mg dextromethorphan and 100 mg mephenytoin to determine their pharmacogenetic status with respect to their hepatic drug oxidizing systems (cytochrome P-450IID6 and P-450 MP). Two patients were poor metabolizers (PMs) of dextromethorphan and three of mephenytoin. Treatment with either psychotropic drug was without significant effect on the metabolism of mephenytoin, but both amitriptyline and thioridazine increased significantly the metabolic ratio of dextromethorphan/dextrorphan. Thioridazine had the effect of changing the pharmacogenetic status of 15 efficient metabolizers of dextromethorphan to poor metabolizers; amitriptyline did not have such an effect. There was no significant correlation between day-11 plasma levels of thioridazine, mesoridazine, or sulforidazine and the metabolism of dextromethorphan, but there was a correlation between the metabolism of dextromethorphan and plasma levels of amitriptyline and nortriptyline. Amitriptyline (p < 0.05), but not thioridazine, decreases the ratio of conjugated/total dextrorphan in urine. Therefore, the dextromethorphan pharmacogenetic test can be used for clinical purposes, but to avoid artefacts it should be done after a washout period, especially after treatment with thioridazine; testing with mephenytoin is less likely to be influenced by thioridazine or amitriptyline.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 40 条
[1]   ROLE OF OXIDATION POLYMORPHISM ON BLOOD AND URINE CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITES IN MAN [J].
BALANTGORGIA, AE ;
SCHULZ, P ;
DAYER, P ;
BALANT, L ;
KUBLI, A ;
GERTSCH, C ;
GARRONE, G .
ARCHIV FUR PSYCHIATRIE UND NERVENKRANKHEITEN, 1982, 232 (03) :215-222
[2]   AMITRIPTYLINE PHARMACOKINETICS AND CLINICAL-RESPONSE .1. FREE AND TOTAL PLASMA AMITRIPTYLINE AND NORTRIPTYLINE [J].
BAUMANN, P ;
JONZIERPEREY, M ;
KOEB, L ;
LE, PK ;
TINGUELY, D ;
SCHOPF, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1986, 1 (02) :89-101
[3]   GC AND GC-MS PROCEDURES FOR SIMULTANEOUS PHENOTYPING WITH DEXTROMETHORPHAN AND MEPHENYTOIN [J].
BAUMANN, P ;
JONZIERPEREY, M .
CLINICA CHIMICA ACTA, 1988, 171 (2-3) :211-222
[4]   AMITRIPTYLINE PHARMACOKINETICS AND CLINICAL-RESPONSE .2. METABOLIC POLYMORPHISM ASSESSED BY HYDROXYLATION OF DEBRISOQUINE AND MEPHENYTOIN [J].
BAUMANN, P ;
JONZIERPEREY, M ;
KOEB, L ;
KUPFER, A ;
TINGUELY, D ;
SCHOPF, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1986, 1 (02) :102-112
[5]  
BAUMANN P, 1989, BIOL PSYCHIATRIE, V2, P161
[6]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[7]   SPARTEINE OXIDATION IS PRACTICALLY ABOLISHED IN QUINIDINE-TREATED PATIENTS [J].
BRINN, R ;
BROSEN, K ;
GRAM, LF ;
HAGHFELT, T ;
OTTON, SV .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (02) :194-197
[8]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[9]   QUINIDINE KINETICS AFTER A SINGLE ORAL DOSE IN RELATION TO THE SPARTEINE OXIDATION POLYMORPHISM IN MAN [J].
BROSEN, K ;
DAVIDSEN, F ;
GRAM, LF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (02) :248-253
[10]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547